Product Description
Carbetocin is a long-acting synthetic agonist analogue of human oxytocin, with antihemorrhagic and uterotonic activities. Upon administration, carbetocin targets, binds to and activates peripheral oxytocin receptors that are present on the smooth musculature of the uterus. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Carbetocin)
Mechanisms of Action: OXTR Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Ferring
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Egypt, France, Germany, Italy, Spain, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Hyperphagia|Prader-Willi Syndrome
Phase 1: Leiomyoma|Postpartum Hemorrhage
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACP-101-303 | P3 |
Enrolling by invitation |
Hyperphagia|Prader-Willi Syndrome |
2029-05-01 |
|
| ACP-101-302 | P3 |
Recruiting |
Prader-Willi Syndrome|Hyperphagia |
2026-05-01 |
|
| ACP-101-302 | P3 |
Unknown Status |
Prader-Willi Syndrome|Hyperphagia |
2025-04-30 |
|
| NCT05924321 | P1 |
Completed |
Postpartum Hemorrhage |
2023-09-21 |